Improved inhibitors of HIV infection

ViroCarb has identified a new class of HIV inhibitors against a new therapeutic target on the HIV envelope protein gp120, present in all HIV, including drug resistant strains. The objective of this internship is to conduct screening studies of libraries, designed based on this new chemical class for optimal efficacy and drug-like properties, using methods previously developed and optimized by the intern. He will also determine the level of anti-HIV activity of leading compounds identified against different HIV strains, including multi-drug resistant strains, and of inhibition of binding of the gp120 protein to the new target. The Result of these studies will be the identification of a lead compound for the development of a drug candidate.

Faculty Supervisor:

Dr. Alan Cochrane

Student:

Alex Chen

Partner:

ViroCarb Inc.

Discipline:

Engineering - biomedical

Sector:

Life sciences

University:

University of Toronto